News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,638 Results
Type
Article (7234)
Company Profile (19)
Press Release (220385)
Section
Business (63333)
Career Advice (299)
Deals (14798)
Drug Delivery (28)
Drug Development (36873)
Employer Resources (26)
FDA (6430)
Job Trends (4944)
News (122133)
Policy (11658)
Tag
2024 BioMidwest Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
Academia (570)
Adcomms (7)
Allergies (35)
Alliances (14827)
ALS (25)
Alzheimer's disease (590)
Antibody-drug conjugate (ADC) (32)
Approvals (6471)
Artificial intelligence (94)
Autoimmune disease (7)
Automation (2)
Bankruptcy (147)
Best Places to Work (4640)
BIOSECURE Act (1)
Biosimilars (18)
Biotechnology (21)
Bladder cancer (44)
Brain cancer (13)
Breast cancer (98)
Cancer (1038)
Cardiovascular disease (61)
Career advice (261)
Career pathing (4)
CAR-T (84)
Cell therapy (208)
Cervical cancer (11)
Clinical research (31104)
Collaboration (278)
Compensation (79)
Complete response letters (7)
COVID-19 (739)
CRISPR (17)
C-suite (66)
Cystic fibrosis (40)
Data (1173)
Denatured (1)
Depression (16)
Diabetes (101)
Diagnostics (2229)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (40)
Drug pricing (42)
Drug shortages (17)
Duchenne muscular dystrophy (36)
Earnings (33243)
Editorial (13)
Employer branding (2)
Employer resources (21)
Events (30874)
Executive appointments (210)
FDA (7031)
Featured Employer (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (249)
Gene editing (45)
Generative AI (9)
Gene therapy (123)
GLP-1 (178)
Government (1263)
Grass and pollen (2)
Guidances (32)
Healthcare (6152)
Huntington's disease (4)
IgA nephropathy (14)
Immunology and inflammation (32)
Indications (15)
Infectious disease (799)
Inflammatory bowel disease (58)
Inflation Reduction Act (5)
Influenza (25)
Intellectual property (42)
Interviews (46)
IPO (8031)
IRA (17)
Job creations (576)
Job search strategy (224)
Kidney cancer (7)
Labor market (5)
Layoffs (40)
Leadership (3)
Legal (2099)
Liver cancer (37)
Lung cancer (146)
Lymphoma (68)
Management (7)
Manufacturing (92)
MASH (34)
Medical device (4574)
Medtech (4575)
Mergers & acquisitions (7090)
Metabolic disorders (262)
Multiple sclerosis (33)
NASH (8)
Neurodegenerative disease (22)
Neuropsychiatric disorders (4)
Neuroscience (770)
NextGen: Class of 2025 (1504)
Non-profit (716)
Northern California (1178)
Now hiring (8)
Obesity (132)
Opinion (73)
Ovarian cancer (53)
Pain (32)
Pancreatic cancer (45)
Parkinson's disease (59)
Partnered (4)
Patents (112)
Patient recruitment (54)
Peanut (17)
People (14499)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9924)
Phase II (13685)
Phase III (10288)
Pipeline (631)
Podcasts (3)
Policy (29)
Postmarket research (797)
Preclinical (3604)
Press Release (9)
Prostate cancer (45)
Psychedelics (11)
Radiopharmaceuticals (119)
Rare diseases (151)
Real estate (1011)
Recruiting (8)
Regulatory (9117)
Reports (13)
Research institute (511)
Resumes & cover letters (39)
Rett syndrome (2)
RNA editing (2)
RSV (14)
Schizophrenia (24)
Series A (40)
Series B (27)
Service/supplier (2)
Sickle cell disease (21)
Southern California (1036)
Special edition (3)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (676)
Stomach cancer (5)
Supply chain (21)
The Weekly (1)
United States (9852)
Vaccines (171)
Venture capitalists (5)
Webinars (1)
Weight loss (74)
Women's health (6)
Worklife (4)
Date
Today (53)
Last 7 days (352)
Last 30 days (1293)
Last 365 days (16228)
2025 (3648)
2024 (17011)
2023 (19154)
2022 (22299)
2021 (23709)
2020 (21869)
2019 (14478)
2018 (10671)
2017 (11484)
2016 (9566)
2015 (11758)
2014 (8115)
2013 (5889)
2012 (6047)
2011 (6771)
2010 (6267)
Location
Africa (177)
Alabama (15)
Alaska (2)
Arizona (50)
Arkansas (3)
Asia (17555)
Australia (4860)
California (2657)
Canada (1058)
China (218)
Colorado (114)
Connecticut (155)
Delaware (54)
Europe (27974)
Florida (383)
Georgia (67)
Idaho (6)
Illinois (190)
India (19)
Indiana (116)
Japan (87)
Kansas (14)
Kentucky (5)
Louisiana (4)
Maine (34)
Maryland (330)
Massachusetts (1907)
Michigan (50)
Minnesota (98)
Missouri (33)
Montana (11)
Nebraska (8)
Nevada (37)
New Hampshire (36)
New Jersey (916)
New Mexico (3)
New York (841)
North Carolina (377)
North Dakota (2)
Northern California (1178)
Ohio (57)
Oklahoma (1)
Oregon (7)
Pennsylvania (634)
Puerto Rico (4)
Rhode Island (7)
South America (302)
South Carolina (8)
Southern California (1036)
Tennessee (37)
Texas (396)
Utah (64)
Virginia (71)
Washington D.C. (16)
Washington State (326)
West Virginia (2)
Wisconsin (10)
227,638 Results for "csl limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
European Commission Approves CSL’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
February 13, 2025
·
6 min read
Press Releases
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 17, 2025
·
6 min read
Press Releases
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
December 16, 2024
·
4 min read
Policy
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
CSL Seqirus, a business of CSL, was selected by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to complete the fill and finish process of pre-pandemic vaccine for the U.S. government as part of the National Pre-Pandemic Influenza Vaccine Stockpile program.
May 30, 2024
·
8 min read
Press Releases
CSL Behring’s Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
February 7, 2025
·
10 min read
Press Releases
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
December 9, 2024
·
5 min read
Drug Development
CSL Heart Attack Hopeful Fails to Meet Primary Endpoint in Phase III Trial
CSL’s investigational cholesterol efflux enhancer CSL112 failed to reduce major adverse cardiovascular events within 90 days in patients who had just suffered a heart attack.
February 12, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
February 21, 2025
·
5 min read
Business
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world’s first approved sa-mRNA COVID-19 vaccine.
May 20, 2024
·
6 min read
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
1 of 22,764
Next